Book contents
- Stahl’s Self-Assessment Examination in Psychiatry
- Stahl’s Self-Assessment Examination in Psychiatry
- Copyright page
- Contents
- Introduction/Preface
- CME Information
- 1 Basic Neuroscience
- 2 Psychosis and Schizophrenia and Antipsychotics
- 3 Unipolar Depression and Antidepressants
- 4 Bipolar Disorder and Mood Stabilizers
- 5 Anxiety Disorders and Anxiolytics
- 6 Chronic Pain and its Treatment
- 7 Disorders of Sleep and Wakefulness and Their Treatment
- 8 Attention Deficit Hyperactivity Disorder (ADHD) and its Treatment
- 9 Dementia and Cognitive Function and its Treatment
- 10 Substance Use and Impulsive Compulsive Disorders and their Treatment
- Optional Posttests and CME Certificates
- Index
- References
3 - Unipolar Depression and Antidepressants
Published online by Cambridge University Press: 19 October 2021
Book contents
- Stahl’s Self-Assessment Examination in Psychiatry
- Stahl’s Self-Assessment Examination in Psychiatry
- Copyright page
- Contents
- Introduction/Preface
- CME Information
- 1 Basic Neuroscience
- 2 Psychosis and Schizophrenia and Antipsychotics
- 3 Unipolar Depression and Antidepressants
- 4 Bipolar Disorder and Mood Stabilizers
- 5 Anxiety Disorders and Anxiolytics
- 6 Chronic Pain and its Treatment
- 7 Disorders of Sleep and Wakefulness and Their Treatment
- 8 Attention Deficit Hyperactivity Disorder (ADHD) and its Treatment
- 9 Dementia and Cognitive Function and its Treatment
- 10 Substance Use and Impulsive Compulsive Disorders and their Treatment
- Optional Posttests and CME Certificates
- Index
- References
Summary
A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
- Type
- Chapter
- Information
- Stahl's Self-Assessment Examination in PsychiatryMultiple Choice Questions for Clinicians, pp. 89 - 148Publisher: Cambridge University PressPrint publication year: 2019
References
References
Stahl, SM. Stahl’s essential psychopharmacology, fourth edition. New York, NY: Cambridge University Press; 2013. (Chapter 7)1Google Scholar
Zimmerman, M, McGlinchey, JB, Posternak, MA, Friedman, M, Attiullah, N, Boerescu, D. How should remission from depression be defined? The depressed patient’s perspective. Am J Psychiatry 2006;163: 148–50.2Google Scholar
References
Stahl, SM. Stahl’s essential psychopharmacology, fourth edition. New York, NY: Cambridge University Press; 2013. (Chapter 7)1Google Scholar
References
Bhattacharya, A, Derecki, NC, Lovenberg, TW, Drevets, WC. Role of neuro-immunological factors in the pathophysiology of mood disorders. Psychopharmacology (Berl) 2016;233(9):1623–36.1Google Scholar
Dowlati, Y, Herrmann, N, Swardfager, JW, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010;67:446–57.2Google Scholar
Haroon, E, Raison, CL, Miller, AH. Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior. Neuropsychopharmacology 2012;37:137–62.3CrossRefGoogle Scholar
Howren, MB, Lamkin, DM, Suls, J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med 2009;71:171–86.4Google Scholar
Raison, CL, Miller, AH. Is depression an inflammatory disorder? Curr Psychiatry Rep 2011;13:467–75.5Google Scholar
References
Stahl, SM. Vasomotor symptoms and depression in women, part 1: role of vasomotor symptoms in signaling the onset or relapse of a major depressive episode. J Clin Psychiatry 2009;70(1):11–2.1Google ScholarPubMed
Stahl, SM. Vasomotor symptoms and depression in women, part 2: treatments that cause remission and prevent relapses of major depressive episodes overlap with treatments for vasomotor symptoms. J Clin Psychiatry 2009;70(3):310–1.2Google ScholarPubMed
References
Serretti, A, Mandelli, L. Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry 2010;71(10): 1259–72.1Google Scholar
Stahl, SM. Stahl’s essential psychopharmacology, the prescriber’s guide, sixth edition. New York, NY: Cambridge University Press; 2017.2Google Scholar
References
Shulman, KI, Walker, SE. Refining the MAOI diet: tyramine content of pizzas and soy products. J Clin Psychiatry 1999;60(3):191–3.1CrossRefGoogle ScholarPubMed
Shulman, KI, Walker, SE. A reevaluation of dietary restrictions for irreversible monoamine oxidase inhibitors. Psychiatr Ann 2001;31(6): 378–84.2CrossRefGoogle Scholar
Shulman, KI, Walker, SE, MacKenzie, S, Knowles, S. Dietary restriction, tyramine, and the use of monoamine oxidase inhibitors. J Clin Psychopharmacol 1989;9(6):397–402.3CrossRefGoogle ScholarPubMed
References
Dvir, Y, Smallwood, P. Serotonin syndrome: a complex but easily avoidable condition. Gen Hosp Psychiatry 2008;30(3):284–7.1Google Scholar
Stahl, SM. Stahl’s essential psychopharmacology, fourth edition. New York, NY: Cambridge University Press; 2013. (Chapter 7)2Google Scholar
Stahl, SM. Stahl’s essential psychopharmacology, the prescriber’s guide, sixth edition. New York, NY: Cambridge University Press; 2017.3Google Scholar
Wimbiscus, M, Kostenkjo, O, Malone, D. MAO inhibitors: risks, benefits, and lore. Cleveland Clinic J Med 2010;77(12):859–82.4Google Scholar
References
Stahl, SM. Stahl’s essential psychopharmacology, fourth edition. New York, NY: Cambridge University Press; 2013. (Chapter 7)1Google Scholar
Thanacoody, HK, Thomas, SH. Tricyclic antidepressant poisoning: cardiovascular toxicity. Toxicol Rev 2005;24(3):205–14.2Google Scholar
References
Stahl, SM. Stahl’s essential psychopharmacology, fourth edition. New York, NY: Cambridge University Press; 2013. (Chapter 7)1Google Scholar
Stahl, SM. Stahl’s essential psychopharmacology, the prescriber’s guide, sixth edition. New York, NY: Cambridge University Press; 2017.2Google Scholar
References
Kennedy, SH, Rizvi, S. Sexual dysfunction, depression, and the impact of antidepressants. J Clin Psychopharmacol 2009;29(2):157–64.1CrossRefGoogle ScholarPubMed
Serretti, A, Chiesa, A. Sexual side effects of pharmacological treatment of psychiatric diseases.Clin Pharmacol Ther 2011;89(1):142–7.2Google Scholar
References
Artigas, F. Serotonin receptors involved in antidepressant effects. Pharmacol Ther 2013;137:119–31.1CrossRefGoogle ScholarPubMed
Carr, GV, Lucki, I. The role of serotonin receptor subtypes in treating depression: a review of animal studies. Psychopharmacology 2011;213: 265–8.2CrossRefGoogle ScholarPubMed
Ciranna, L. Serotonin as a modulator of glutamate- and GABA-mediated neurotransmission: implications in physiological functions and in pathology. Curr Neuropharmacol 2006;4(2):101–14.3Google Scholar
Ohno, Y, Shimizu, S, Tokudome, K. Pathophysiological roles of serotonergic system in regulating extrapyramidal motor functions. Biol Pharm Bull 2013;36(9):1396–400.4Google Scholar
Shimizu, S, Mizuguchi, Y, Ohno, Y. Improving the treatment of schizophrenia: role of 5HT receptors in modulating cognitive and extrapyramidal motor functions. CNS Neurol Dis Drug Targets 2013;12: 861–9.5Google Scholar
Siarey, RJ, Andreasen, M, Lambert, JD. Serotoninergic modulation of excitability in area CA1 of the in vitro rat hippocampus. Neurosci Lett 1995;199(3):211–4.6CrossRefGoogle ScholarPubMed
Stahl, SM. Stahl’s essential psychopharmacology, fourth edition. New York, NY: Cambridge University Press; 2013.7Google Scholar
Zhou, FM, Hablitz, JJ. Activation of serotonin receptors modulates synaptic transmission in rat cerebral cortex. J Neurophysiol 1999;82(6): 2989–99.8CrossRefGoogle ScholarPubMed
References
Bech, P, Fava, M, Trivedi, MH, Wisniewski, SR, Rush, AJ. Outcomes on the pharmacopsychometric triangle in bupropion-SR vs. buspirone augmentation of citalopram in the STAR*D trial. Acta Psychiatr Scand 2012;125(4):342–8.1Google Scholar
Citrome, L. Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Postgrad Med 2010;122(4):39–48.2Google Scholar
Trivedi, MH, Cutler, AJ, Richards, C et al. A randomized controlled trial of the efficacy and safety of lisdexamfetamine dimesylate as augmentation therapy in adults with residual symptoms of major depressive disorder after treatment with escitalopram. J Clin Psychiatry 2013;74(8):802–9.3Google Scholar
References
Artigas, F. Serotonin receptors involved in antidepressant effects. Pharmacol Ther 2013;137:119–31.1CrossRefGoogle ScholarPubMed
Morehouse, R, Macqueen, G, Kennedy, SH. Barriers to achieving treatment goals: a focus on sleep disturbance and sexual dysfunction. J Affect Disord 2011;132(Suppl 1):S14–20.2CrossRefGoogle ScholarPubMed
Ohno, Y, Shimizu, S, Tokudome, K. Pathophysiological roles of serotonergic system in regulating extrapyramidal motor functions. Biol Pharm Bull 2013;36(9):1396–400.3Google Scholar
Shimizu, S, Mizuguchi, Y, Ohno, Y. Improving the treatment of schizophrenia: role of 5HT receptors in modulating cognitive and extrapyramidal motor functions. CNS Neurol Dis Drug Targets 2013;12: 861–9.4Google Scholar
Stahl, SM. Stahl’s essential psychopharmacology, fourth edition. New York, NY: Cambridge University Press; 2013.5Google Scholar
References
Berlim, MT, Van den Eynde, F, Daskalakis, JZ. Clinically meaningful efficacy and acceptability of low-frequency repetitive transcranial magnetic stimulation (rTMS) for treating primary major depression: a meta-analysis of randomized, double-blind and sham-controlled trials. Neuropsychopharmacology 2013;38:543–51.1CrossRefGoogle ScholarPubMed
Blumberger, DM, Mulsant, BH, Daskalakis, ZJ. What is the role of brain stimulation therapies in the treatment of depression? Curr Psychiatry Rep 2013;15(7):368.2CrossRefGoogle ScholarPubMed
Kalu, UG, Sexton, CE, Loo, CK, Ebmeier, KP. Transcranial direct current stimulation in the treatment of major depression: a meta-analysis. Psychological Med 2012;42(9):1791–800.3CrossRefGoogle ScholarPubMed
O’Reardon, JP, Solvason, HB, Janicak, PG et al. Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biol Psychiatry 2007;62(11):1208–16.4Google Scholar
References
Gelenberg, AJ, Freeman, MP, Markowitz, JC et al. Practice guideline for the treatment of patients with major depressive disorder, third edition. APA; 2010.1Google Scholar
Husain, MM, Rush, AJ, Fink, M et al. Speed of response and remission in major depressive disorder with acute electroconvulsive therapy (ECT): a Consortium for Research in ECT (CORE) report. J Clin Psychiatry 2004;65(4):485–91.2CrossRefGoogle Scholar
Marangell, LB, Martinez, M, Jurdi, RA, Zboyan, H. Neurostimulation therapies in depression: a review of new modalities. Acta Psychiatr Scand 2007;116:174–81.3Google Scholar
References
Sarkisyan, G, Roberts, AJ, Hedlund, PB. The 5-HT7 receptor as a mediator and modulator of antidepressant-like behavior. Behav Brain Res 2010;209(1):99–108.1Google Scholar
Stahl, SM. The serotonin-7 receptor as a novel therapeutic target. J Clin Psychiatry 2010;71(11):1414–5.2CrossRefGoogle ScholarPubMed
References
Sansone, RA, Sansone, LA. SSRI-induced indifference. Psychiatry (Edgemont) 2010;7(1):14–8.1Google ScholarPubMed
Stahl, SM. Case studies: Stahl’s essential psychopharmacology. New York, NY: Cambridge University Press; 2011.2Google Scholar
Stahl, SM. Stahl’s essential psychopharmacology, fourth edition. New York, NY: Cambridge University Press; 2013. (Chapter 7)3Google Scholar
Stahl, SM. Stahl’s essential psychopharmacology, the prescriber’s guide, sixth edition. New York, NY: Cambridge University Press; 2017.4Google Scholar
References
Abdallah, CG, Adams, TG, Kelmendi, B, Esterlis, I, Sanacora, G, Krystal, JH. Ketamine’s mechanism of action: a path to rapid-acting antidepressants. Depress Anxiety 2016;33(8):689–97.1Google Scholar
Barbon, A, Caracciolo, L, Orlandi, C, et al. Chronic antidepressant treatments induce a time-dependent up-regulation of AMPA receptor subunit protein levels. Neurochem Int 2011;59(6):896–905.2CrossRefGoogle ScholarPubMed
Bunney, BG, Bunney, WE. Rapid-acting antidepressant strategies: mechanisms of action. Int J Neuropsychopharmacol 2012;15(5):695–713.3CrossRefGoogle ScholarPubMed
Racagni, G, Popoli, M. Cellular and molecular mechanisms in the long-term action of antidepressants. Dialogues Clin Neurosci 2008;10(4):385–400.4Google Scholar
Stahl, SM. Stahl’s essential psychopharmacology, fourth edition. New York, NY: Cambridge University Press; 2013.5Google Scholar
References
Baune, B, Hohoff, C, Berger, K et al. Association of the COMT val158met variant with antidepressant treatment response in major depression. Neuropsychopharmacology 2008;33:924–32.1Google Scholar
Kato, M, Serretti, A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry 2010;15:473–500.2CrossRefGoogle ScholarPubMed
Kirchheiner, J, Nickchen, K, Bauer, M et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 2004;9:442–73.3Google Scholar
Kocabas, NA, Faghel, C, Barreto, M et al. The impact of catechol-O-methyltransferase SNPs and haplotypes on treatment response phenotypes in major depressive disorder: a case-control association study. Int Clin Psychopharmacol 2010;25(4):218–27.4Google Scholar
Nutt, D, Demyttenaere, K, Janka, Z et al. The other face of depression, reduced positive affect: the role of catecholamines in causation and cure. J Psychopharmacol 2006;21(5):461–71.5Google Scholar
References
Byatt, N, Deligiannidis, KM, Freeman, MP. Antidepressant use in pregnancy: a critical review focused on risks and controversies. Acta Psychiatr Scand 2013;127:94–114.1CrossRefGoogle ScholarPubMed
Gentile, S, Galbally, M. Prenatal exposure to antidepressant medications and neurodevelopmental outcomes: a systematic review. J Affective Disord 2011;128:1–9.2Google Scholar
Grigoriadis, S, Vonderporten, EH, Mamisashvili, L et al. Prenatal exposure to antidepressants and persistent pulmonary hypertension of the newborn: systematic review and meta-analysis. BMJ 2014;348:f6932.3CrossRefGoogle ScholarPubMed
Huybrechts, KF, Palmsten, K, Avorn, J et al. Antidepressant use in pregnancy and the risk of cardiac defects. N Engl J Med 2014;370(25): 2397–407.4Google Scholar
References
DeBodinat, C, Guardiola-Lemaitre, B, Mocaer, E et al. Agomelatine, the first melatonergic antidepressant: discovery, characterization, and development. Nature Reviews Drug Discov 2010;9:628–42.1Google Scholar